TMOD4: Potential Drug Targets for Alzheimer's, Parkinson's and Schizophrenia

Target Name: TMOD4

NCBI ID: G29765

TMOD4

TMOD4: Potential Drug Targets for Alzheimer's, Parkinson's and Schizophrenia

TMOD4 (Sk-Tmod) is a protein that is expressed in the brain and is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. TMOD4 has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. As a result, TMOD4 has potential as a drug target or biomarker for these disorders.

The protein TMOD4 is composed of 154 amino acids and has a calculated molecular weight of 19.9 kDa. TMOD4 is expressed in the brain and is primarily localized to the postsynaptic terminal of dendrites in the cerebral cortical regions. It is also found in the choroid plexus, which is a network of small blood vessels in the ventricles of the brain. TMOD4 is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Synaptic plasticity is critical for the development and progression of many neurological disorders. For example, in Alzheimer's disease, the loss of synaptic plasticity is thought to contribute to the progression of the disease and the development of neurodegeneration. In Parkinson's disease, the loss of synaptic plasticity is also thought to contribute to the progression of the disease and the development of neurodegeneration. In schizophrenia, the loss of synaptic plasticity is also thought to contribute to the development and progression of the disease.

TMOD4 has been shown to play a role in the regulation of synaptic plasticity in several ways. For example, TMOD4 has been shown to promote the formation of new neurons in the brain, which is thought to be a key component of synaptic plasticity. also been shown to regulate the activity of neural circuits in the brain, which is thought to be a key component of synaptic plasticity. Finally, TMOD4 has been shown to play a role in the regulation of neurotransmitter release, which is a key component of synaptic plasticity.

In addition to its role in the regulation of synaptic plasticity, TMOD4 has also been shown to play a role in the development and progression of several neurological disorders. For example, TMOD4 has been shown to be involved in the development and progression of Alzheimer's disease, as well as in the development and progression of Parkinson's disease and schizophrenia.

TMOD4 has also been shown to have potential as a drug target or biomarker for these disorders. For example, TMOD4 has been shown to be involved in the development and progression of Alzheimer's disease, and therefore has potential as a drug target for this disorder. Additionally , TMOD4 has been shown to be involved in the development and progression of Parkinson's disease, and has potential as a drug target for this disorder. Furthermore, TMOD4 has been shown to be involved in the development and progression of schizophrenia, and has potential as a drug target for this disorder.

In conclusion, TMOD4 is a protein that is involved in the regulation of synaptic plasticity and has potential as a drug target or biomarker for several neurological disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Further research is needed to fully understand the role of TMOD4 in these disorders and to develop effective treatments.

Protein Name: Tropomodulin 4

Functions: Blocks the elongation and depolymerization of the actin filaments at the pointed end. The Tmod/TM complex contributes to the formation of the short actin protofilament, which in turn defines the geometry of the membrane skeleton

The "TMOD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMOD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets